HomeHealthAkebia Therapeutics to Present Virtually at the H.C. Wainwright 24th Annual Global...

Akebia Therapeutics to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference

Published on

<br /> Akebia Therapeutics to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference<br />

PR Newswire



CAMBRIDGE, Mass.


,


Sept. 1, 2022


/PRNewswire/ —

Akebia Therapeutics, Inc.

(Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that

John Butler

, Chief Executive Officer, will present virtually at the H.C. Wainwright 24

th

Annual Global Investment Conference. The hybrid conference will take place September 12–14, 2022.

The presentation will be available on-demand beginning

September 12, 2022

through the Investors section of Akebia’s website at

https://ir.akebia.com

for approximately 90 days.


About Akebia Therapeutics


Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in

Cambridge, Massachusetts

. For more information, please visit our website at

www.akebia.com

, which does not form a part of this release.


Akebia Therapeutics Contact



Mercedes Carrasco



[email protected]

Cision
View original content to download multimedia:

https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-virtually-at-the-hc-wainwright-24th-annual-global-investment-conference-301615782.html

SOURCE Akebia Therapeutics

rt Akebia Therapeutics to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference

Featured image: Megapixl © Visivasnc

Disclaimer

Latest News

BD, CerTest Biotec Announce US Commercial Launch of Monkeypox Assay

BD, CerTest Biotec Announce US Commercial Launch of...

Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine® Study

Creative Medical Technology Announces Peer Reviewed Publication of...

Centene Subsidiary Selected to Continue Serving Nebraska’s Medicaid Managed Care Members

Centene Subsidiary Selected to Continue Serving Nebraska's Medicaid...

More like this

Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health Canada

Optimi (CSE:OPTI)(OTCQX:OPTHF)(FRA:8BN) aiming to become the first vertically integrated psychedelics firm to formulate and...

GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr

The exclusive license allows GSK to commercialize tebipenem HBr in...

iBio Acquires RubrYc Therapeutics’ AI Drug Discovery Platform and Pipeline

– Positions Company for leadership in AI-powered drug discovery – ...

CVS Health reports progress against goal to reduce suicide attempts among Aetna members 20% by 2025

CVS Health reports progress against goal to reduce...